In a regulatory filing, WellCare (WCG) said that on September 26, it entered nto an asset purchase agreement and related agreements with Aetna (AET) to acquire Aetna’s entire standalone Medicare Part D prescription drug plan business, effective 11:59 p.m. on December 31, 2018. The Aetna Part D business had an aggregate of approximately 2.2 million members as of June 30, 2018. Per the terms of the agreements, Aetna will provide administrative services to, and retain the financial risk of, the Aetna Part D business through 2019. As a result, under generally accepted accounting principles, WellCare does not expect to recognize any revenue from the Aetna Part D business or it to affect its results of operations until 2020. WellCare expects to fund the full purchase price from a portion of available cash on hand. Aetna is divesting the Aetna Part D business as part of CVS Health Corporation’s (CVS) proposed acquisition of Aetna. As a result, closing of the acquisition of the Aetna Part D business is subject to the closing of the CVS Health Transaction, regulatory approvals and other customary closing conditions.Completion of the CVS Health Transaction remains subject to federal and certain state regulatory approvals required in connection with that acquisition, including by the United States Department of Justice and approvals from certain state departments of insurance and similar regulators, and the satisfaction of all closing conditions.